Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Vascular Medicine and Interventional Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Catheter Cardiovasc Interv. 2022 Mar;99(4):1345-1355. doi: 10.1002/ccd.30091. Epub 2022 Feb 3.
The FlowTriever All-Comer Registry for Patient Safety and Hemodynamics (FLASH) is a prospective multi-center registry evaluating the safety and effectiveness of percutaneous mechanical thrombectomy for treatment of pulmonary embolism (PE) in a real-world patient population (NCT03761173). This interim analysis reports outcomes for the first 250 patients enrolled in FLASH.
High- and intermediate-risk PEs are characterized by high mortality rates, frequent readmissions, and long-term sequelae. Mechanical thrombectomy is emerging as a front-line therapy for PE that enables immediate thrombus reduction while avoiding the bleeding risks inherent with thrombolytics.
The primary endpoint is a composite of major adverse events (MAE) including device-related death, major bleeding, and intraprocedural device- or procedure-related adverse events at 48 h. Secondary endpoints include on-table changes in hemodynamics and longer-term measures including dyspnea, heart rate, and cardiac function.
Patients were predominantly intermediate-risk per ESC guidelines (6.8% high-risk, 93.2% intermediate-risk). There were three MAEs (1.2%), all of which were major bleeds that resolved without sequelae, with no device-related injuries, clinical deteriorations, or deaths at 48 h. All-cause mortality was 0.4% at 30 days, with a single death that was unrelated to PE. Significant on-table improvements in hemodynamics were noted, including an average reduction in mean pulmonary artery pressure of 7.1 mmHg (22.2%, p < 0.001). Patient symptoms and cardiac function improved through follow-up.
These interim results provide preliminary evidence of excellent safety in a real-world PE population. Reported outcomes suggest that mechanical thrombectomy can result in immediate hemodynamic improvements, symptom reduction, and cardiac function recovery.
FlowTriever 全人群肺栓塞患者安全与血液动力学注册研究(FLASH)是一项前瞻性多中心注册研究,旨在评估经皮机械血栓切除术治疗真实世界肺栓塞(PE)患者的安全性和有效性(NCT03761173)。本中期分析报告了 FLASH 研究中前 250 例入组患者的结局。
高危和中危 PE 的死亡率高,常需再入院,且存在长期后遗症。机械血栓切除术作为一种一线治疗方法,在避免溶栓固有出血风险的同时,可实现即时血栓减少。
主要终点为包括 48 小时内与器械相关的死亡、主要出血以及术中器械或操作相关不良事件在内的复合主要不良事件(MAE)。次要终点包括血液动力学即时变化以及更长时间的呼吸困难、心率和心功能等指标。
患者主要符合 ESC 指南的中危标准(6.8%为高危,93.2%为中危)。发生 3 例 MAE(1.2%),均为大出血,无不良后果,无器械相关损伤、临床恶化或 48 小时内死亡。30 天全因死亡率为 0.4%,唯一死亡病例与 PE 无关。术中血液动力学显著改善,平均肺动脉压平均降低 7.1mmHg(22.2%,p<0.001)。患者症状和心功能在随访中得到改善。
这些中期结果为真实世界 PE 人群中提供了出色安全性的初步证据。报告的结局表明,机械血栓切除术可即时改善血液动力学,减轻症状,恢复心功能。